Health
Wells Fargo Report Says GLP-1s Reducing Certain Surgeries
Key Points
Robin Wenzel, head of Wells Fargo Industry Insights, said that the rise of GLP-1s has brought down the rate of bariatric surgery by more than 30%, providing a less invasive 'pharmaceutical offramp' for weight management. Wenzel said GLP-1 use rose 120% between 2022 and 2024 and that it offers the parts of the healthcare industry an opportunity to turn to helping patients manage medication or their side effects.
Robin Wenzel, head of Wells Fargo Industry Insights, said that the rise of GLP-1s has brought down the rate of bariatric surgery by more than 30%, providing a less invasive 'pharmaceutical offramp' for weight management. Wenzel said GLP-1 use rose 120% between 2022 and 2024 and that it offers the parts of the healthcare industry an opportunity to turn to helping patients manage medication or their side effects. (Source: Bloomberg)